Uproleselan

DB14829InvestigationalSmall molecule

Uproleselan is a novel, specific E-Selectin antagonist under investigation in clinical trial NCT02306291 (Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML).

Mechanism: Pharmacologically active on E-selectin
Curator reviewed
Formula / weight: C₆₀H₁₀₉N₃O₂₇ · 1304.526 g/mol (avg)
Code names: GMI-1271

Resolves to

Compound

UNIIPE952ANF83CAS1983970-12-2ChEMBLCHEMBL3989971

Structure

InChIKeyLYSYOXNOOPBOSC-NGSKMYNLSA-NSMILES

CC[C@H]1C[C@H](C[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O[C@@H](CC3CCCCC3)C(O)=O)[C@H]2NC(C)=O)[C@@H]1O[C@@H]1O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]1O)C(=O)NCCNC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC

Targets

P16581SELE

What you can answer from here — as of September 13, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

16Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Uproleselan, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account